Skip to main content

ARCpoint: Top 10 Undervalued Medical Diagnostics & Research Industry Stocks (ARC)

AI-generated - The Globe and Mail - Mon Mar 24, 2025

ARCpoint is now ranked among the top 10 undervalued stocks in the Medical Diagnostics & Research industry on the Toronto Stock Exchange or TSX Venture Exchange.

  • A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
  • Valuation methodology provided by Stockcalc (see below)

Medical Diagnostics & Research: Companies that provide laboratory testing services through imaging and other diagnostic services to the medical industry.

Stocks in this category are held primarily for capital appreciation.

SymbolNameClose Price ($)Valuation ($)DifferenceAverage Vol (30D)Market Cap ($M)Yield (%)P/E Ratio
AVCRAvricore Health0.050.090.04 (84.4%)738905.00.00.0
ARCARCpoint0.070.080.01 (12.4%)179637.10.00.0

All data provided as of March 24, 2025.
The list is sorted by stocks with the greatest percentage difference between valuation and price.

ARCpoint

ARCpoint Inc is a US-based franchise system providing drug testing, alcohol screening, DNA and clinical lab testing, corporate wellness programs, and employment and background screening, among other services. The platform also digitalizes and streamlines administrative functions such as materials purchasing, compliance, billing, and physician services for ARCpoint franchise labs and other clients.

ARCpoint is listed under ARC on the TSX Venture Exchange.

Stockcalc

StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.

Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:

  • Discounted Cash Flow (DCF)
  • Price & Other Comparables
  • Multiples
  • Adjusted Book Value (ABV)
  • Analyst Consensus

Artificial Intelligence at Report on Business

Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.